الفهرس 
Title : Outcome of early gastric cancer patients in relation to biological mar
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Background: Gastric Cancer is a lethal heterogenous malignancy that affects elderly males more than females and carry bad prognosis. Aims: To repost the experience of the Egyptian National Cancer Institute in managing early gastric cancer, also investigating the expression of TP53 and C-met and their relations to Survival of patients. Patients and Methods: This study included 66 cases with early gastric adenocarcinoma presented to the NCI between 2014 and 2017, P53 and C-met expression were assessed by immunohistochemistry and their relation with disease free survival and over-all survival was the secondary end point. Results: Sixty six patients underwent gastrectomy for gastric adenocarcinoma were included in the study. P53 was positive in 37 (56.1%) and C-met was positive in 36 (54.5%) cases. Median DFS was 17.4 months for the whole group and was significantly better with adjuvant treatment (median DFS was 22 months for post-operative therapy and 4.9 months for pre-operative and 11.4 months for perioperative therapy P=0.006) and also with radiotherapy administration median DFS was 19.7 months and 8 months without radiotherapy P=0.05) . Median OS was 27.4 months for the whole group and was better with negative lymph nodes (median OS was not reached in negative nodes vs 8.2 months in node positive P=0.03) and cases responding to chemotherapy had better OS (19.8 months for who had complete response or regressive disease vs 7.5 months for stable disease P=0.04) Median OS was better for P53 mutation (40.8 months in positive P53 vs 18.9 months in negative P53 P=0.05) C-met did not exhibit any prognostic significance. Conclusions: Patients with negative Lymph nodes and mutated P53 had better OS; also patients with better response to neoadjuvant chemotherapy had better OS. Patients received adjuvant chemotherapy had better DFS, also those who received RTH had better DFS. C-met had no prognostic significance